Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.

Emily A KendallShelly MalhotraSarah Cook-ScaliseClaudia M DenkingerDavid W Dowdy

Published in: BMC infectious diseases (2019)

Novel regimens such as BPaMZ could improve RR-TB outcomes and shorten treatment for all patients, particularly with universal use. Decision-makers weighing early options for implementing such regimens at scale will want to consider the expected impact on patient outcomes and on the burden of treatment in their local context.

Keyphrases

mycobacterium tuberculosis
end stage renal disease
type diabetes
newly diagnosed
emergency department
climate change
insulin resistance
drug induced
human immunodeficiency virus